New Submissions Are Not Currently Being Accepted
Samples sent after April 10, 2024 will be put on hold.
Viewing desktop version: Switch to Mobile
Molly Rocks
Sold as: Molly
ID: 12521
Result Photo Detail Photo
GC/MS Graph
Detail Photo
GC/MS Graph
Detail Photo
Test Date: Apr 04, 2022
Pub. Date: Apr 04, 2022
Src Location: San Jose, CA
Submitter Loc: San Jose, CA
United States
Color: Clear / White
Size: 50 mg, 18.88 mm x 7.06 mm
Data Source: DrugsData
Tested by: DDL
Lab's ID: 22030074
Sold as: Molly
Expected to be: Not Specified
Lab comments:
Unidentified Substance #1: 1 part (tentatively identified as a variant of 2'-Fluoro-2-oxo-PCE)

Unidentified Substance #2: 20 parts (since identified as 2'-Fluoro-2-oxo-PCE after first being misidentified as 3'-Fluoro-2-oxo-PCE)

White crystalline powder chunks in capsule.
Apr 27 2023: This sample was originally reported as containing Fluorexetamine (3-Fluoro-2-oxo PCE). A certified reference standard became available for 2-Fluoro-2-oxo PCE in early 2023.

All samples analyzed by the DrugsData lab prior to early 2023 that were reported as containing Fluorexetamine have been reexamined in comparison to this new standard. They have all been retroactively revised; they all contain 2-Fluoro-2-oxo PCE, including this sample. To date, no samples tested by DrugsData have contained 3-Fluoro-2-oxo PCE.

Dec 20 2022: The secondary unidentified may be a positional isomer of the more abundant one. (thank you, Y.)

May 5 2022: Fluorexetamine has been confirmed by comparison to certified reference standard.

Apr 22 2022: Unidentified substance has been tentatively identified as Fluorextamine with the second chemical likely the hydroxylimine variant of the parent compound (thank you, K.). We are working to finalize this identification.